The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
This study describes a validation of the BD Onclarity HPV (Onclarity) assay using the international guidelines for HPV test requirements for cervical cancer screening of women 30 years old and older using Danish SurePath screening samples. The clinical specificity (0.90, 95% confidence interval [CI] = 0.88 to 0.91) and sensitivity (0.97, 95% CI = 0.87 to 1.0) of the Onclarity assay were shown to be not inferior to the reference assay (specificity, 0.90 [95% CI = 0.88 to 0.92]; sensitivity, 0.98 [95% CI = 0.91 to 1.0]). The intralaboratory reproducibility of Onclarity was 97%, with a lower confidence bound of 96% (kappa value, 0.93). The interlaboratory agreement was 97%, with a lower confidence bound of 95% (kappa value, 0.92). The BD Onclarity HPV assay fulfills all the international guidelines for a new HPV test to be used in primarily screening. This is the first clinical validation of a new HPV assay using SurePath screening samples, and thus the Onclarity HPV assay is the first HPV assay to hold an international validation for both SurePath and ThinPrep.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Mant, J., Doust, J., Roalfe, A., Barton, P., Cowie, M., Glasziou, P., Mant, D., McManus, R., Holder, R., Deeks, J., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13320 · Cited by 498
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Arbyn, M., Snijders, P. J. F., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Kocjan, B. J., & Poljak, M. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.04.015 · Cited by 275 · cited 1×
“However, only a select few assays have obtained the clinical validation in accordance with the international guidelines (7).”
BackgroundComparing the performance of six human papillomavirus tests in a screening population
Cuzick, J., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Ho, L., Terry, G., Liddle, S., Wright, C., Lyons, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.22 · Cited by 211
Rebolj, M., Preisler, S., Ejegod, D. M., Rygaard, C., Lynge, E., & Bonde, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086835 · Cited by 74
Self-citationEjegod, D. M., Junge, J., Franzmann, M., Kirschner, B., Bottari, F., Sideri, M., Sandri, M.-T., & Bonde, J. (2016) · Papillomavirus Research · doi:10.1016/j.pvr.2016.01.003 · Cited by 42
Self-citationEvaluation of a New DNA Test for Detection of Carcinogenic Human Papillomavirus
Castle, P. E., Gutierrez, E. C., Leitch, S. V., Maus, C. E., McMillian, R. A., Nussbaumer, W. A., Vaughan, L. M., Wheeler, C. M., Gravitt, P. E., & Schiffman, M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00422-11 · Cited by 33
Cited by
2020 list of human papillomavirus assays suitable for primary cervical cancer screening
Arbyn, M., Simon, M., Peeters, E., Xu, L., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Bonde, J., Ostrbenk Vanlencak, A., Zhao, F.-H., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.031 · Cited by 284
Self-citationBonde, J. H., Sandri, M.-T., Gary, D. S., & Andrews, J. C. (2020) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000494 · Cited by 149
Self-citationBonde, J., Ejegod, D. M., Cuschieri, K., Dillner, J., Heideman, D. A. M., Quint, W., Pavon Ribas, M. A., Padalko, E., Christiansen, I. K., Xu, L., et al. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.09.012 · Cited by 44
Self-citationBonde, J. H., Pedersen, H., Quint, W., Xu, L., Arbyn, M., & Ejegod, D. M. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01518-19 · Cited by 37
Self-citationDemarco, M., Carter-Pokras, O., Hyun, N., Castle, P. E., He, X., Dallal, C. M., Chen, J., Gage, J. C., Befano, B., Fetterman, B., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01910-17 · Cited by 29
Metadata
- Authors
- Ejegod, D., Bottari, F., Pedersen, H., Sandri, M. T., & Bonde, J.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2016-09
- Volume
- 54
- Issue
- 9
- Pages
- 2267-2272
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2517570535
- Cited by
- 40
- References
- 9
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening. https://app.cochat.ai/papers/10.1128/jcm.00508-16
- The paper
- Ejegod, D., Bottari, F., Pedersen, H., Sandri, M. T., & Bonde, J. (2016). The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00508-16
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.